WO2002020573A2 - Nucleotide sequences which code for the gpmb gene - Google Patents
Nucleotide sequences which code for the gpmb gene Download PDFInfo
- Publication number
- WO2002020573A2 WO2002020573A2 PCT/EP2001/009453 EP0109453W WO0220573A2 WO 2002020573 A2 WO2002020573 A2 WO 2002020573A2 EP 0109453 W EP0109453 W EP 0109453W WO 0220573 A2 WO0220573 A2 WO 0220573A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gene
- codes
- polynucleotide
- sequence
- amino acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/04—Alpha- or beta- amino acids
- C12P13/08—Lysine; Diaminopimelic acid; Threonine; Valine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/90—Isomerases (5.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y504/00—Intramolecular transferases (5.4)
- C12Y504/02—Phosphotransferases (phosphomutases) (5.4.2)
- C12Y504/02001—Phosphoglycerate mutase (5.4.2.1)
Definitions
- the invention provides nucleotide sequences from coryneform bacteria which code for the gpmB gene and a process for the fermentative preparation of amino acids using bacteria in which the gpmB gene is enhanced.
- L-Amino acids are used in human medicine and in the pharmaceuticals Industry, in the foodstuffs industry and especially in animal nutrition.
- amino acids are prepared by fermentation from strains of coryneform bacteria, in particular Corynebacterium glutamicum. Because of their great importance, work is constantly being undertaken to improve the preparation processes. Improvements to the process can relate to fermentation measures, such as, for example, stirring and supply of oxygen, or the composition of the nutrient media, such as, for example, the sugar concentration during the fermentation, or the working up to the product form by, for example, ion exchange chromatography, or the intrinsic output properties of the microorganism itself.
- fermentation measures such as, for example, stirring and supply of oxygen
- the composition of the nutrient media such as, for example, the sugar concentration during the fermentation
- the working up to the product form by, for example, ion exchange chromatography or the intrinsic output properties of the microorganism itself.
- Methods of mutagenesis, selection and mutant selection are used to improve the output properties of these microorganisms. Strains which are resistant to antimetabolites or are auxotrophic for metabolites of regulatory importance and produce amino acids are obtained in this manner.
- the inventors had the object of providing new measures for improved fermentative preparation of amino acids.
- L-amino acids or amino acids are mentioned in the following, this means one or more amino acids, including their salts, chosen from the group consisting of L- asparagine, L-threonine, L-serine, L-glutamate, L-glycine, L-alanine, L-cysteine, L-valine, L-methionine, L- isoleucine, L-leucine, L-tyrosine, L-phenylalanine, L- histidine, L-lysine, L-tryptophan and L-arginine. L-Lysine is particularly preferred.
- the invention provides an isolated polynucleotide from coryneform bacteria, comprising a polynucleotide sequence which codes for the gpmB gene, chosen from the group consisting of
- polynucleotide which is identical to the extent of at least 70% to a polynucleotide which codes for a polypeptide which comprises the amino acid sequence of SEQ ID No. 2,
- polynucleotide which codes for a polypeptide which comprises an amino acid sequence which is identical to the extent of at least 70 % to the amino acid sequence of SEQ ID No. 2,
- polynucleotide comprising at least 15 successive nucleotides of the polynucleotide sequence of a) , b) or c) , the polypeptide preferably having the activity of phosphoglycerate mutase II.
- the invention also provides the above-mentioned polynucleotide, this preferably being a DNA which is capable of replication, comprising:
- the invention also provides
- a polynucleotide in particular DNA, which is capable of replication and comprises the nucleotide sequence as shown in SEQ ID No. 1;
- polynucleotide which codes for a polypeptide which comprises the amino acid sequence as shown in SEQ ID No. 2;
- a vector containing the polynucleotide according to the invention in particular a shuttle vector or plasmid vector, and
- coryneform bacteria which contain the vector or in which the gpmB gene is enhanced.
- the invention also provides polynucleotides which substantially comprise a polynucleotide sequence, which are obtainable by screening by means of hybridization of a corresponding gene library of a coryneform bacterium, which comprises the complete gene or parts thereof, with a probe which comprises the sequence of the polynucleotide according to the invention according to SEQ ID No. 1 or a fragment thereof, and isolation of the polynucleotide sequence mentioned.
- Polynucleotides which comprise the sequences according to the invention are suitable as hybridization probes for RNA, cDNA, and DNA, in order to isolate, in the full length, nucleic acids or polynucleotides or genes which code for phosphoglycerate mutase II or to isolate those nucleic acids or polynucleotides or genes which have a high similarity of sequence with that of the gpmB gene. They are also suitable for incorporation into so-called “arrays”, “micro arrays” or “DNA chips”, in order to detect and determine the corresponding polynucleotides.
- Polynucleotides which comprise the sequences according to the invention are furthermore suitable as primers with the aid of which DNA of genes which code for phosphoglycerate mutase II can be prepared by the polymerase chain reaction (PCR) .
- PCR polymerase chain reaction
- Such oligonucleotides which serve as probes or primers comprise at least 25, 26, 27, 28, 29 or 30, preferably at least 20, 21, 22, 23 or 24, very particularly preferably at least 15, 16, 17, 18 or 19 successive nucleotides.
- Oligonucleotides which have a length of at least 31, 32, 33, 34, 35, 36, 37, 38, 39 or 40, or at least 41, 42, 43, 44, 45, 46, 47, 48, 49 or 50 nucleotides are also suitable. Oligonucleotides with a length of at least 100, 150, 200, 250 or 300 nucleotides are optionally also suitable.
- Polynucleotide in general relates to polyribonucleotides and polydeoxyribonucleotides, it being possible for these to be non-modified RNA and DNA or modified RNA and DNA.
- the polynucleotides according to the invention include a polynucleotide according to SEQ ID No. 1 or a fragment prepared therefrom and also those which are at least 70 % to 80%, preferably at least 81% to 85%, particularly preferably at least 86% to 90%, and very particularly preferably at least 91%, 93%, 95%, 97% or 99% identical to the polynucleotide according to SEQ ID No. 1 or a fragment prepared therefrom.
- Polypeptides are understood as meaning peptides or proteins which comprise two or more amino acids bonded via peptide bonds.
- polypeptides according to the invention include a polypeptide according to SEQ ID No. 2, in particular those with the biological activity of phosphoglycerate mutase II and also those which are at least 70% to 80%, preferably at least 81% to 85%, particularly preferably at least 86% to 90%, and very particularly preferably at least 91%, 93%, 95%, 97% or 99% identical to the polypeptide according to SEQ ID No. 2 and have the activity mentioned.
- the invention furthermore relates to a process for the fermentative preparation of amino acids chosen from the group consisting of L-asparagine, L-threonine, L-serine, L- glutamate, L-glycine, L-alanine, L-cysteine, L-valine, L- methionine, L-isoleucine, L-leucine, L-tyrosine, L- phenylalanine, L-histidine, L-lysine, L-tryptophan and L- arginine using coryneform bacteria which in particular already produce amino acids and in which the nucleotide sequences which code for the gpmB gene are enhanced, in particular over-expressed.
- amino acids chosen from the group consisting of L-asparagine, L-threonine, L-serine, L- glutamate, L-glycine, L-alanine, L-cysteine, L-valine, L- methionine, L-isole
- enhancement in this connection describes the increase in the intracellular activity of one or more enzymes (proteins) in a microorganism which are coded by the corresponding DNA, for example by increasing the number of copies of the gene or genes, using a potent promoter or using a gene or allele which codes for a corresponding enzyme (protein) having a high activity, and optionally combining these measures.
- the activity or concentration of the corresponding protein is in general increased by at least 10%, 25%, 50%, 75%, 100%, 150%, 200%, 300%, 400% or 500%, up to a maximum of 1000% or 2000%, based on that of the wild-type protein or the activity or concentration of the protein in the starting microorganism.
- the microorganisms which the present invention provides can produce L-amino acids from glucose, sucrose, lactose, fructose, maltose, molasses, starch, cellulose or from glycerol and ethanol. They can be representatives of coryneform bacteria, in particular of the genus
- Corynebacterium Of the genus Corynebacterium, there may be mentioned in particular the species Corynebacterium glutamicum, which is known among experts for its ability to produce L-amino acids .
- Suitable strains of the genus Corynebacterium in particular of the species Corynebacterium glutamicum (C. glutamicum) , are in particular the known wild-type strains
- the new gpmB gene from C. glutamicum which codes for the enzyme phosphoglycerate mutase II (E.C. 5.4.2.1) has been isolated.
- E. coli Escherichia coli
- the setting up of gene libraries is described in generally known textbooks and handbooks. The textbook by Winnacker: Gene und Klone, Amsterdam Einf ⁇ hrung in die Gentechnologie [Genes and Clones, An Introduction to Genetic Engineering] (Verlag Chemie, Weinheim, Germany, 1990), or the handbook by Sambrook et al.: Molecular Cloning, A Laboratory Manual (Cold Spring Harbor Laboratory Press, 1989) may be mentioned as an example.
- a well-known gene library is that of the E. coli K-12 strain W3110 set up in ⁇ vectors by Kohara et al.
- plasmids such as pBR 322 (Bolivar, Life Sciences, 25, 807-818 (1979)) or p ⁇ C9 (Vieira et al., 1982, Gene, 19:259-268).
- Suitable hosts are, in particular, those E. coli strains which are restriction- and recombination-defective.
- An example of these is the strain DH5 mcr, which has been described by Grant et al. (Proceedings of the National Academy of Sciences USA, 87 (1990) 4645-4649) .
- the long DNA fragments cloned with the aid of cosmids can in turn be subcloned in the usual vectors suitable for sequencing and then sequenced, as is described e.g. by Sanger et al . (Proceedings of the National Academy of Sciences of the United States of America, 74:5463-5467, 1977).
- the new DNA sequence of C. glutamicum which codes for the gpmB gene and which, as SEQ ID No. 1, is a constituent of the present invention has been found.
- the amino acid sequence of the corresponding protein has furthermore been derived from the present DNA sequence by the methods described above.
- the resulting amino acid sequence of the gpmB gene product is shown in SEQ ID No. 2.
- Coding DNA sequences which result from SEQ ID No. 1 by the degeneracy of the genetic code are also a constituent of the invention.
- DNA sequences which hybridize with SEQ ID No. 1 or parts of SEQ ID No. 1 are a constituent of the invention.
- Conservative amino acid exchanges such as e.g. exchange of glycine for alanine or of aspartic acid for glutamic acid in proteins, are furthermore known among experts as "sense mutations" which do not lead to a fundamental change in the activity of the protein, i.e. are of neutral function. It is furthermore known that changes on the N and/or C terminus of a protein cannot substantially impair or can even stabilize the function thereof.
- DNA sequences which hybridize with SEQ ID No. 1 or parts of SEQ ID No. 1 are a constituent of the invention.
- DNA sequences which are prepared by the polymerase chain reaction (PCR) using primers which result from SEQ ID No. 1 are a constituent of the invention.
- PCR polymerase chain reaction
- Such oligonucleotides typically have a length of at least 15 nucleotides.
- the hybridization takes place under stringent conditions, that is to say only hybrids in which the probe and target sequence, i. e. the polynucleotides treated with the probe, are at least 70 % identical are formed. It is known that the stringency of the hybridization, including the washing steps, is influenced or determined by varying the buffer composition, the temperature and the salt concentration. The hybridization reaction is preferably carried out under a relatively low stringency compared with the washing steps (Hybaid Hybridisation Guide, Hybaid Limited, Teddington, UK, 1996) .
- a 5 x SCC buffer at a temperature of approx. 50°C - 68°C, for example, can be employed for the hybridization reaction.
- Probes can also hybridize here with polynucleotides which are less than 70% identical to the sequence of the probe. Such hybrids are less stable and are removed by washing under stringent conditions. This can be achieved, for example, by lowering the salt concentration to 2 x SSC and optionally subsequently 0.5 x SSC (The DIG System User's Guide for Filter Hybridisation, Boehringer Mannheim, Mannheim, Germany, 1995) a temperature of approx. 50°C - 68°C being established. It is optionally possible to lower the salt concentration to 0.1 x SSC.
- Polynucleotide fragments which are, for example, at least 70 % or at least 80 % or at least 90 % to 95 % identical to the sequence of the probe employed can be isolated by increasing the hybridization temperature stepwise from 50°C to 68°C in steps of approx. 1 - 2°C. Further instructions on hybridization are obtainable on the market in the form of so-called kits (e. g. DIG Easy Hyb from Roche Diagnostics GmbH, Mannheim, Germany, Catalogue No. 1603558) .
- kits e. g. DIG Easy Hyb from Roche Diagnostics GmbH, Mannheim, Germany, Catalogue No. 1603558
- PCR polymerase chain reaction
- coryneform bacteria produce amino acids in an improved manner after over-expression of the gpmB gene .
- the number of copies of the corresponding genes can be increased, or the promoter and regulation region or the ribosome linking site upstream of the structural gene can be mutated.
- Expression cassettes which are incorporated upstream of the structural gene act in the same way.
- inducible promoters it is additionally possible to increase the expression in the course of fermentative amino acid production.
- the expression is likewise improved by measures to prolong the life of the m- RNA.
- the enzyme activity is also increased by preventing the degradation of the enzyme protein.
- the genes or gene constructs can either be present in plasmids with a varying number of copies, or can be integrated and amplified in the chromosome. Alternatively, an over- expression of the genes in question can furthermore be achieved by changing the composition of the media and the culture procedure.
- Suitable plasmids are those which are replicated in coryneform bacteria.
- Numerous known plasmid vectors such as e. g. pZl (Menkel et al., Applied and Environmental Microbiology (1989) 64:549-554), pEKExl (Eikmanns et al., Gene 102:93-98 (1991)) or pHS2-l (Sonnen et al., Gene 107:69-74 (1991)) are based on the cryptic plasmids pHM1519, pBLl or pGAl .
- plasmid vectors such as e.g. those based on pCG4 (US-A 4,489,160), or pNG2 (Serwold-Davis et al . , FEMS Microbiology Letters 66, 119- 124 (1990)), or pAGl (US-A 5,158,891), can be used in the same manner.
- Plasmid vectors which are furthermore suitable are also those with the aid of which the process of gene amplification by integration into the chromosome can be used, as has been described, for example, by Reinscheid et co to > M M M n o C ⁇ O C ⁇ O c ⁇
- L- a ino acids in addition to the enhancement of the gpmB gene, for one or more of the genes chosen from the group consisting of:
- the term "attenuation" in this connection describes the reduction or elimination of the intracellular activity of one or more enzymes (proteins) in a microorganism which are coded by the corresponding DNA, for example by using a weak promoter or using a gene or allele which codes for a corresponding enzyme with a low activity or inactivates the corresponding gene or enzyme (protein) , and optionally combining these measures.
- the activity or concentration of the corresponding protein is in general reduced to 0 to 75%, 0 to 50%, 0 to 25%, 0 to 10% or 0 to 5% of the activity or concentration of the wild-type protein or of the activity or concentration of the protein in the starting microorganism.
- the invention also provides the microorganisms prepared according to the invention, and these can be cultured continuously or discontinuously in the batch process (batch culture) or in the fed batch (feed process) or repeated fed batch process (repetitive feed process) for the purpose of production of amino acids.
- batch culture batch culture
- feed process fed batch
- repetitive feed process repeated fed batch process
- the culture medium to be used must meet the requirements of the particular strains in a suitable manner. Descriptions of culture media for various microorganisms are contained in the handbook "Manual of Methods for General CO NO r M M o c ⁇ o C ⁇ O C ⁇
- Suitable substances having a selective action can be added to the medium to maintain the stability of plasmids.
- oxygen or oxygen-containing gas mixtures such as e.g. air, are introduced into the culture.
- the temperature of the culture is usually 20°C to 45°C, and preferably 25°C to 40°C. Culturing is continued until a maximum of the desired product has formed. This target is usually reached within 10 hours to 160 hours.
- the process according to the invention is used for fermentative preparation of amino acids.
- DSMZ German Collection of Microorganisms and Cell Cultures, Braunschweig, Germany
- composition of the usual nutrient media such as LB or TY medium, can also be found in the handbook by Sambrook et al.
- the cosmid DNA was then cleaved with the restriction enzyme BamHI (Amersham Pharmacia, Freiburg, Germany Product Description BamHI, Code no. 27-0868-04) .
- BamHI Amersham Pharmacia, Freiburg, Germany Product Description BamHI, Code no. 27-0868-04
- the cosmid DNA treated in this manner was mixed with the treated ATCC13032 DNA and the batch was treated with T4 DNA ligase (Amersham Pharmacia, Freiburg, Germany, Product Description T4-DNA-
- Ligase Code no. 27-0870-04
- the ligation mixture was then packed in phages with the aid of Gigapack II XL Packing Extract (Stratagene, La Jolla, USA, Product Description Gigapack II XL Packing Extract, Code no. 200217) .
- Gigapack II XL Packing Extract Stratagene, La Jolla, USA, Product Description Gigapack II XL Packing Extract, Code no. 200217
- the cells were taken up in 10 mM MgS0 4 and mixed with an aliquot of the phage suspension.
- the infection and titering of the cosmid library were carried out as described by Sambrook et al . (1989, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor) , the cells being plated out on LB agar (Lennox, 1955, Virology, 1:190) with 100 mg/1 ampicillin. After incubation overnight at 37°C, recombinant individual clones were selected.
- the cosmid DNA of an individual colony was isolated with the Qiaprep Spin Miniprep Kit (Product No. 27106, Qiagen, Hilden, Germany) in accordance with the manufacturer's instructions and partly cleaved with the restriction enzyme Sau3AI (Amersham Pharmacia, Freiburg, Germany, Product Description Sau3AI, Product No. 27-0913-02) .
- the DNA fragments were dephosphorylated with shrimp alkaline phosphatase (Roche Diagnostics GmbH, Mannheim, Germany, Product Description SAP, Product No. 1758250) .
- the cosmid fragments in the size range of 1500 to 2000 bp were isolated with the QiaExII Gel Extraction Kit (Product No. 20021, Qiagen, Hilden, Germany) .
- the DNA of the sequencing vector pZero-1 obtained from Invitrogen (Groningen, Holland, Product Description Zero Background Cloning Kit, Product No. K2500-01) , was cleaved with the restriction enzy BamHI (Amersham Pharmacia, Freiburg, Germany, Product Description BamHI, Product No. 27-0868-04) .
- the ligation of the cosmid fragments in the sequencing vector pZero-1 was carried out as described by Sambrook et al. (1989, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor) , the DNA mixture being incubated overnight with T4 ligase (Pharmacia Biotech, Freiburg, Germany) . This ligation mixture was then electroporated (Tauch et al.
- the plasmid preparation of the recombinant clones was carried out with the Biorobot 9600 (Product No. 900200, Qiagen, Hilden Germany) .
- the sequencing was carried out by the dideoxy chain-stopping method of Sanger et al. (1977, Proceedings of the National Academy of Sciences U.S.A.,
- the raw sequence data obtained were then processed using the Staden program package (1986, Nucleic Acids Research, 14:217:231) version 97-0.
- the individual sequences of the pZerol derivatives were assembled to a continuous contig.
- the computer-assisted coding region analysis was prepared with the XNIP program (Staden, 1986, Nucleic Acids Research, 14:217-231).
- the resulting nucleotide sequence is shown in SEQ ID No. 1. Analysis of the nucleotide sequence showed an open reading frame of 705 base pairs, which was called the gpmB gene.
- the gpmB gene codes for a protein of 235 amino acids.
- chromosomal DNA was isolated by the method of Eikmanns et al. (Microbiology 140: 1817-1828 (1994) ) .
- the following oligonucleotides were chosen for the polymerase chain reaction (see SEQ ID No. 3 and SEQ ID No. 4) :
- gpmBexl 5 " ca ggtacc tgg eta cga gga cga tta ag 3 gpmBex2 : 5' tg tctaga aag cat gcg gag gaa tea ac 3"
- the primers shown were synthesized by MWG-Biotech AG (Ebersberg, Germany) and the PCR reaction was carried out by the standard PCR method of Innis et al. (PCR Protocols. A Guide to Methods and Applications, 1990, Academic Press) with Pwo-Polymerase from Roche Diagnostics GmbH (Mannheim, Germany) . With the aid of the polymerase chain reaction, the primers allow amplification of a DNA fragment 827 bp in size, which carries the gpmB gene.
- the primer gpmBexl contains the sequence for the cleavage site of the restriction endonuclease Kpnl, and the primer gpmBex2 the cleavage site of the restriction endonuclease Xbal, which are marked by underlining in the nucleotide sequence shown above.
- the gpmB fragment 827 bp in size was cleaved with the restriction endonucleases Kpnl and Xbal and then isolated from the agarose gel with the QiaExII Gel Extraction Kit (Product No. 20021, Qiagen, Hilden, Germany) .
- the E. coli - C. glutamicum shuttle vector pEC-XK99E was constructed according to the prior art.
- the vector contains the replication region rep of the plasmid pGAl including the replication effector per (US-A-5, 175, 108; Nesvera et al., Journal of Bacteriology 179, 1525-1532 (1997)), the kanamycin resistance gene aph(3')-Ha from Escherichia coli (Beck et al .
- the trc promoter can be induced by addition of the lactose derivative IPTG (isopropyl ?-D-thiogalactopyranoside) .
- the E. coli - C. glutamicum shuttle vector pEC-XK99E constructed was transferred into C. glutamicum DSM5715 by means of electroporation (Liebl et al., 1989, FEMS Microbiology Letters, 53:299-303). Selection of the transfor ants took place on LBHIS agar comprising 18.5 g/l brain-heart infusion broth, 0.5 M sorbitol, 5 g/l Bacto- tryptone, 2.5 g/l Bacto-yeast extract, 5 g/l NaCl and 18 g/l Bacto-agar, which had been supplemented with 25 mg/1 kanamycin. Incubation was carried out for 2 days at 33°C.
- Plasmid DNA was isolated from a transformant by conventional methods (Peters-Wendisch et al., 1998, Microbiology, 144, 915 - 927), cleaved with the restriction endonuclease Hindlll, and the plasmid was checked by subsequent agarose gel electrophoresis.
- the plasmid construct obtained in this way was called pEC- XK99E (figure 1) .
- CD ro ⁇ 3 -J 3 ⁇ d CD •*» ⁇ -J s: s: a rt cn hj 0 tO li Cfl 3 ⁇ ⁇
- the strain DSM5715 was transformed with the plasmid pEC- XK99EgpmBalex using the electroporation method described by Liebl et al., (FEMS Microbiology Letters, 53:299-303 (1989) ) . Selection of the transformants took place on LBHIS agar comprising 18.5 g/l brain-heart infusion broth, 0.5 M sorbitol, 5 g/l Bacto-tryptone, 2.5 g/l Bacto-yeast extract, 5 g/l NaCl and 18 g/l Bacto-agar, which had been supplemented with 25 mg/1 kanamycin. Incubation was carried out for 2 days at 33°C.
- Plasmid DNA was isolated from a transformant by conventional methods (Peters-Wendisch et al., 1998, Microbiology, 144, 915 - 927), cleaved with the restriction endonucleases Xbal and Kpnl, and the plasmid was checked by subsequent agarose gel electrophoresis. The strain obtained was called DSM5715/pEC-XK99EgpmBalex.
- the C. glutamicum strain DSM5715/pEC-XK99EgpmBalex obtained in example 4 was cultured in a nutrient medium suitable for the production of lysine and the lysine content in the culture supernatant was determined.
- the strain was first incubated on an agar plate with the corresponding antibiotic (brain-heart agar with kanamycin (25 mg/1)) for 24 hours at 33°C.
- a preculture was seeded (10 ml medium in a 100 ml conical flask) .
- the complete medium Cglll was used as the medium for the preculture.
- Kanamycin 25 mg/1 was added to this.
- the preculture was incubated for 16 hours at 33°C at 240 rpm on a shaking machine.
- a main culture was seeded from this preculture such that the initial OD (660nm) of the main culture was 0.1.
- Medium MM was used for the main culture.
- MOPS morpholinopropanesulfonic acid
- the CSL, MOPS and the salt solution were brought to pH 7 with aqueous ammonia and autoclaved.
- the sterile substrate and vitamin solutions were then added, as well as the CaC0 3 autoclaved in the dry state.
- Culturing is carried out in a 10 ml volume in a 100 ml conical flask with baffles. Kanamycin (25 mg/1) and IPTG (lmM/1) was added. Culturing was carried out at 33°C and 80% atmospheric humidity.
- the OD was determined at a measurement wavelength of 660 nm with a Biomek 1000 (Beckmann Instruments GmbH, Kunststoff) .
- the amount of lysine formed was determined with an amino acid analyzer from Eppendorf- BioTronik (Hamburg, Germany) by ion exchange chromatography and post-column derivation with ninhydrin detection.
- FIG. 1 Map of the plasmid pEC-XK99E
- Kan Kanamycin resistance gene aph(3 , )-IIa from Escherichia coli
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2001295470A AU2001295470A1 (en) | 2000-09-09 | 2001-08-16 | Nucleotide sequences which code for the gpmb gene |
EP01976088A EP1315825A2 (en) | 2000-09-09 | 2001-08-16 | Nucleotide sequences which code for the gpmb gene |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10044772 | 2000-09-09 | ||
DE10044772.4 | 2000-09-09 | ||
DE10133668A DE10133668A1 (en) | 2000-09-09 | 2001-07-11 | Nucleotide sequences encoding the gpmB gene |
DE10133668.3 | 2001-07-11 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002020573A2 true WO2002020573A2 (en) | 2002-03-14 |
WO2002020573A3 WO2002020573A3 (en) | 2002-05-16 |
Family
ID=26007003
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2001/009453 WO2002020573A2 (en) | 2000-09-09 | 2001-08-16 | Nucleotide sequences which code for the gpmb gene |
Country Status (4)
Country | Link |
---|---|
US (1) | US20020052486A1 (en) |
EP (1) | EP1315825A2 (en) |
AU (1) | AU2001295470A1 (en) |
WO (1) | WO2002020573A2 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8647642B2 (en) | 2008-09-18 | 2014-02-11 | Aviex Technologies, Llc | Live bacterial vaccines resistant to carbon dioxide (CO2), acidic PH and/or osmolarity for viral infection prophylaxis or treatment |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0387527A1 (en) * | 1989-03-14 | 1990-09-19 | Degussa Aktiengesellschaft | Process for the fermentative production of L-lysine |
DE19929365A1 (en) * | 1999-06-25 | 2000-12-28 | Basf Lynx Bioscience Ag | New genes from Corynebacterium glutamicum, useful for modifying cells for production of primary or secondary metabolites, e.g. amino or fatty acids |
WO2001000843A2 (en) * | 1999-06-25 | 2001-01-04 | Basf Aktiengesellschaft | Corynebacterium glutamicum genes encoding metabolic pathway proteins |
EP1106693A1 (en) * | 1999-12-09 | 2001-06-13 | Degussa AG | Nucleotide sequence encoding the zwa2 protein |
EP1108790A2 (en) * | 1999-12-16 | 2001-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Novel polynucleotides |
-
2001
- 2001-08-16 WO PCT/EP2001/009453 patent/WO2002020573A2/en not_active Application Discontinuation
- 2001-08-16 EP EP01976088A patent/EP1315825A2/en not_active Withdrawn
- 2001-08-16 AU AU2001295470A patent/AU2001295470A1/en not_active Abandoned
- 2001-09-07 US US09/947,442 patent/US20020052486A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0387527A1 (en) * | 1989-03-14 | 1990-09-19 | Degussa Aktiengesellschaft | Process for the fermentative production of L-lysine |
DE19929365A1 (en) * | 1999-06-25 | 2000-12-28 | Basf Lynx Bioscience Ag | New genes from Corynebacterium glutamicum, useful for modifying cells for production of primary or secondary metabolites, e.g. amino or fatty acids |
WO2001000843A2 (en) * | 1999-06-25 | 2001-01-04 | Basf Aktiengesellschaft | Corynebacterium glutamicum genes encoding metabolic pathway proteins |
EP1106693A1 (en) * | 1999-12-09 | 2001-06-13 | Degussa AG | Nucleotide sequence encoding the zwa2 protein |
EP1108790A2 (en) * | 1999-12-16 | 2001-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Novel polynucleotides |
Non-Patent Citations (2)
Title |
---|
EIKMANNS B J ET AL: "MOLECULAR ASPECTS OF LYSINE, THREONINE, AND ISOLEUCINE BIOSYNTHESIS IN CORYNEBACTERIUM GLUTAMICUM" ANTONIE VAN LEEUWENHOEK, DORDRECHT, NL, vol. 64, no. 2, 1993, pages 145-163, XP000918559 * |
KRAMER R: "Genetic and physiological approaches for the production of amino acids" JOURNAL OF BIOTECHNOLOGY, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 45, no. 1, 12 February 1996 (1996-02-12), pages 1-21, XP004036833 ISSN: 0168-1656 * |
Also Published As
Publication number | Publication date |
---|---|
WO2002020573A3 (en) | 2002-05-16 |
AU2001295470A1 (en) | 2002-03-22 |
EP1315825A2 (en) | 2003-06-04 |
US20020052486A1 (en) | 2002-05-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1315745B1 (en) | Recombinant coryneform bacteria overexpressing the glyceraldehyde-3-phosphate dehydrogenase -2 gene , and their use in l-lysine production | |
US20020055152A1 (en) | Nucleotide sequences which code for the 11dD2 gene | |
US6916636B2 (en) | Nucleotide sequences which code for the oxyR gene | |
EP1317549B1 (en) | Isolation and sequencing of the ptsi gene of c. glutamicum | |
US20050221450A1 (en) | Methods of making L-amino acids in coryneform bacteria using the sigE gene | |
US6777206B2 (en) | Nucleotide sequences which code for the RodA protein | |
US20020106760A1 (en) | Nucleotide sequences which code for the dps gene | |
EP1217069A2 (en) | Nucleotide sequences which code for the ilvE gene | |
US6727086B2 (en) | Nucleotide sequences which code for the sigH gene | |
WO2002024915A1 (en) | Dcta (c4-dicarboxylate transporter) from corynebacterium glutamicum | |
US20020115159A1 (en) | Nucleotide sequences coding for the ATR61protein | |
WO2002022670A1 (en) | Nucleotide sequences coding for the ftsx gene | |
US20020115160A1 (en) | Nucleotide sequences which code for the truB gene | |
US20020086374A1 (en) | Nucleotide sequences which code for the dep67 gene | |
EP1319077A2 (en) | Nucleotide sequences which code for the tmk gene | |
EP1315825A2 (en) | Nucleotide sequences which code for the gpmb gene | |
WO2002018589A2 (en) | Nucleotide sequence coding for the sigc gene of corynebacterium glutamicum | |
US20020090685A1 (en) | Nucleotide sequences coding for the ndkA gene | |
US20020106755A1 (en) | Nucleotide sequences coding for the sigM gene | |
WO2002042466A2 (en) | Nucleotide sequences coding for the cysq gene | |
WO2002024919A1 (en) | Nucleotide sequences coding for the thya gene | |
EP1311683B1 (en) | Nucleotide sequences which code for the csta gene from corynebacterium glutamicum | |
WO2002022632A2 (en) | Nucleotide sequences coding for the pknd gene | |
WO2002034775A2 (en) | Nucleotide sequences encoding the hemd and hemb genes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2001976088 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2001976088 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001976088 Country of ref document: EP |